Loading…
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $134M | $-36M | $-39M | $-19M | -14.1% | -3.9% | 41.8% |
| 2024 | $140M | $-24M | $-27M | $-22M | -9.8% | 57.1% | -43.5% |
| 2023 | $89M | $-41M | $-49M | $-46M | -30.3% | 81.8% | -27.2% |
| 2022 | $49M | $-58M | $-67M | $-61M | -74.3% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 49 | 89.08 | 139.93 | 134.48 |
| Operating Revenue | - | 49 | 89.08 | 139.93 | 134.48 |
| Cost Of Revenue | - | 27.68 | 35.31 | 40.98 | 31.47 |
| Gross Profit | - | 21.33 | 53.76 | 98.94 | 103.01 |
| Operating Expense | - | 84.65 | 103.85 | 135.80 | 151.20 |
| Research And Development | - | 25.98 | 29.05 | 34.37 | 38.55 |
| Selling General And Administration | - | 58.66 | 74.80 | 101.43 | 112.65 |
| Total Expenses | - | 112.32 | 139.16 | 176.78 | 182.67 |
| Operating Income | - | -63.32 | -50.08 | -36.86 | -48.19 |
| Total Operating Income As Reported | - | -63.32 | -50.08 | -36.86 | -48.19 |
| EBITDA | - | -57.78 | -41.20 | -23.81 | -35.59 |
| Normalized EBITDA | - | -57.78 | -39.43 | -23.81 | -35.59 |
| EBIT | - | -61.80 | -45.28 | -27.38 | -38.86 |
| Interest Income | - | 1.52 | 6.57 | 9.47 | 9.33 |
| Interest Expense | - | 4.95 | 3.31 | 0.02 | 0.02 |
| Net Interest Income | - | -3.43 | 3.27 | 9.45 | 9.31 |
| Other Income Expense | 7.74 | - | -1.77 | - | - |
| Interest Income Non Operating | - | 1.52 | 6.57 | 9.47 | 9.33 |
| Interest Expense Non Operating | - | 4.95 | 3.31 | 0.02 | 0.02 |
| Net Non Operating Interest Income Expense | - | -3.43 | 3.27 | 9.45 | 9.31 |
| Pretax Income | - | -66.75 | -48.59 | -27.40 | -38.88 |
| Tax Provision | - | 0.01 | 0.02 | 0.05 | 0.07 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -66.76 | -48.61 | -27.46 | -38.94 |
| Net Income From Continuing And Discontinued Operation | - | -66.76 | -48.61 | -27.46 | -38.94 |
| Net Income From Continuing Operation Net Minority Interest | - | -66.76 | -48.61 | -27.46 | -38.94 |
| Net Income | - | -66.76 | -48.61 | -27.46 | -38.94 |
| Net Income Common Stockholders | - | -66.76 | -48.61 | -27.46 | -38.94 |
| Net Income Including Noncontrolling Interests | - | -66.76 | -48.61 | -27.46 | -38.94 |
| Normalized Income | - | -66.76 | -46.84 | -27.46 | -38.94 |
| Diluted NI Availto Com Stockholders | - | -66.76 | -48.61 | -27.46 | -38.94 |
| Basic Average Shares | 13.63 | 27.66 | 34.46 | 38.87 | - |
| Diluted Average Shares | 13.63 | 27.66 | 34.46 | 38.87 | - |
| Reconciled Depreciation | - | 4.02 | 4.08 | 3.58 | 3.27 |
| Reconciled Cost Of Revenue | - | 27.68 | 35.31 | 40.98 | 31.47 |
| Total Unusual Items | - | 0 | -1.77 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | - | 0 | -1.77 | 0 | 0 |
| Special Income Charges | - | 0 | -1.77 | 0 | 0 |
| Other Special Charges | - | - | 1.77 | - | - |
| Gain On Sale Of Security | 7.74 | - | - | - | - |
| Gain On Sale Of Ppe | 0 | - | - | - | - |
| Otherunder Preferred Stock Dividend | 0 | - | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| RxSight, Inc.this co. | RXST | $211M | -5.42 | 0.77 | -14.1% | -5.68 |
| Inhibikase Therapeutics, Inc. | IKT | $219M | -4.54 | 1.27 | -27.9% | -1.50 |
| Voyager Therapeutics, Inc. | VYGR | $219M | -1.83 | 1.12 | -61.1% | -1.49 |
| Utah Medical Products, Inc. | UTMD | $216M | 19.17 | 1.82 | 9.5% | 9.09 |
| Pro-Dex, Inc. | PDEX | $214M | 23.83 |
| - |
| - |
| - |
| - |
| 5.84 |
| 24.5% |
| 16.29 |
| Keros Therapeutics, Inc. | KROS | $213M | 2.45 | 0.70 | 28.7% | -0.83 |
| Atrium Therapeutics, Inc. | RNA | $210M | -2.74 | 1.02 | -37.0% | 0.73 |
| Accendra Health, Inc. | ACH | $203M | -0.18 | -0.44 | 238.8% | 9.29 |
| Sanara MedTech Inc. | SMTI | $203M | -5.40 | 34.13 | -632.5% | 22.72 |
| Peer Median | - | -1.01 | 1.19 | -9.2% | 4.91 | |